LUX-Lung 7: is there enough data for a final conclusion? - Author's reply

Affiliations

¹ Division of Hematology and Oncology, Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea. Electronic address: kpark@skku.edu.

Comment

Keunchil Park. Lancet Oncol. 2016 Jul.

. 2016 Jul;17(7):e268-e269.

doi: 10.1016/S1470-2045(16)30244-3.

¹ Division of Hematology and Oncology, Innovative Cancer Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea. Electronic address: kpark@skku.edu.

No abstract available

Comment on

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Park K, et al. Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. Lancet Oncol. 2016. PMID: 27083334 Clinical Trial.
LUX-Lung 7: is there enough data for a final conclusion?
Di Maio M, Addeo A. Di Maio M, et al. Lancet Oncol. 2016 Jul;17(7):e266. doi: 10.1016/S1470-2045(16)30116-4. Lancet Oncol. 2016. PMID: 27396642 No abstract available.
LUX-Lung 7: is there enough data for a final conclusion?
Hu C, Zhang H, Zhang Y, Wu F, Ma JA. Hu C, et al. Lancet Oncol. 2016 Jul;17(7):e266-e267. doi: 10.1016/S1470-2045(16)30117-6. Lancet Oncol. 2016. PMID: 27396643 No abstract available.
LUX-Lung 7: is there enough data for a final conclusion?
Orlandi A, Calegari MA, Barone C. Orlandi A, et al. Lancet Oncol. 2016 Jul;17(7):e267-e268. doi: 10.1016/S1470-2045(16)30216-9. Lancet Oncol. 2016. PMID: 27396644 No abstract available.